Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

(2019) Yvonne Naegelin et al.   JAMA Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland

(2018) Barbara Scotti et al.   PLoS One

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study

(2018) Bassem I. Yamout et al.   Journal of Immunology Research

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

(2014) Stephen L Hauser   Multiple Sclerosis Journal

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

(2014) Paul Emery et al.   PLoS One

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

(2013) Su-Hyun Kim et al.   JAMA Neurology

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab

(2008) Roy M. Fleischmann   SEMINARS IN ARTHRITIS AND RHEUMATISM